Source-grounded facts extracted from Dare Bioscience, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Dare Bioscience, Inc. shareholders approved Adjournment of meeting to solicit additional proxies for Proposal 6 if necessary at the 2026-06-11 meeting.
“Proposal 8 : Our stockholders approved the adjournment of the Meeting, if necessary or advisable, to solicit additional proxies in favor of Proposal 6 if there were not sufficient votes to approve Proposal 6 by the votes set forth below.”
Dare Bioscience, Inc. shareholders approved Adjournment of meeting to solicit additional proxies for Proposal 5 if necessary at the 2026-06-11 meeting.
“Proposal 7 : Our stockholders approved the adjournment of the Meeting, if necessary or advisable, to solicit additional proxies in favor of Proposal 5 if there were not sufficient votes to approve Proposal 5 by the votes set forth below.”
Dare Bioscience, Inc. shareholders approved Approval of amendment to 2022 Stock Incentive Plan to increase shares available by 1,500,000 at the 2026-06-11 meeting.
“Proposal 6 : Our stockholders approved the 2022 Plan Amendment by the votes set forth below.”
Dare Bioscience, Inc. shareholders approved Approval of potential future issuance of shares under equity line with Lincoln Park Capital Fund, LLC (Nasdaq rule) at the 2026-06-11 meeting.
“Proposal 5 : Our stockholders approved, in accordance with Nasdaq rules, the potential future issuance of shares of our common stock under our existing equity line with Lincoln Park Capital Fund, LLC by the votes set forth below.”
Dare Bioscience, Inc. shareholders approved Advisory vote on preferred frequency of holding advisory vote on executive compensation at the 2026-06-11 meeting.
“Proposal 4 : Our stockholders voted as follows with respect to the preferred frequency of holding an advisory vote on the compensation of our named executive officers.”
Dare Bioscience, Inc. shareholders approved Advisory approval of compensation of named executive officers at the 2026-06-11 meeting.
“Proposal 3 : Our stockholders approved, on an advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement by the votes set forth below.”
Dare Bioscience, Inc. shareholders approved Ratification of appointment of Haskell & White LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
“Proposal 2 : Our stockholders ratified the appointment of Haskell & White LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 by the votes set forth below.”
Dare Bioscience, Inc. shareholders approved Election of Class III directors at the 2026-06-11 meeting.
“Proposal 1 : Each of the director nominees identified in the table below was elected as a Class III director to hold office until our 2029 annual meeting of stockholders, and until their respective successor is duly elected and qualified, by the votes set forth below.”
Dare Bioscience, Inc. reported financial results for the quarter ended March 31, 2026.
“On May 14, 2026, Daré Bioscience, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026, a copy of which is furnished as Exhibit 99.1 to this report.”
Dare Bioscience, Inc. issued 195,010 Investor Units, each consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants to purchase up to 390,020 shares of commo of unit to public investors in Regulation A offering for at an offering price of $5.00 per unit.
“completed closings of its previously announced Regulation A offering of up to 4,854,000 units (each, an “Investor Unit” and collectively the “Investor Units”), each consisting of one share of Series A Convertible Preferred Stock (the “Series A Preferred Stock”) and two warrants, each to purchase one share of our common stock (“Investor Warrants”), with each Investor Unit being offered at an offering price of $5.00 (the “Offering”). The closings occurred on each of May 1, 4, 5 and 6, 2026. In connection therewith, we issued an aggregate of 195,010 Investor Units consisting of 195,010 shares of Series A Preferred Stock and Investor Warrants to purchase up to 390,020 shares of our common stock.”
Dare Bioscience, Inc. issued 20,000 Investor Units, each consisting of one share of Series A Convertible Preferred Stock and two warrants to purchase one share of common stock of unit to investors in the Regulation A offering for $5.00 per unit.
“On April 17, 2026, Daré Bioscience, Inc. (“Daré” “we,” “us,” or “our”) completed a closing of our previously announced Regulation A offering of up to 4,854,000 units (each, an “Investor Unit” and collectively the “Investor Units”), each consisting of one share of Series A Convertible Preferred Stock (the “Series A Preferred Stock”) and two warrants, each to purchase one share of our common stock (“Investor Warrants”), with each Investor Unit being offered at an offering price of $5.00 (the “Offering”). In connection therewith, we issued an aggregate of 20,000 Investor Units consisting of 20,000 shares of Series A Preferred Stock and Investor Warrants to purchase up to 40,000 shares of our common stock.”
Dare Bioscience, Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2026, Daré Bioscience, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2025, a copy of which is furnished as Exhibit 99.1 to this report.”
Dare Bioscience, Inc. issued 43,050 Investor Units consisting of 43,050 shares of Series A Preferred Stock and Investor Warrants to purchase up to 86,100 shares of our common stock of unit for $5.00.
“On March 16, 2026, Daré Bioscience, Inc. (“Daré” “we,” “us,” or “our”) completed a closing of our previously announced Regulation A offering of up to 4,854,000 units (each, an “Investor Unit” and collectively the “Investor Units”), each consisting of one share of Series A Convertible Preferred Stock (the “Series A Preferred Stock”) and two warrants, each to purchase one share of our common stock (“Investor Warrants”), with each Investor Unit being offered at an offering price of $5.00 (the “Offering”). In connection therewith, we issued an aggregate of 43,050 Investor Units consisting of 43,050 shares of Series A Preferred Stock and Investor Warrants to purchase up to 86,100 shares of our common stock.”
Dare Bioscience, Inc.: Filed Certificate of Designation designating 4,999,620 shares as Series A Convertible Preferred Stock, establishing powers, preferences, and rights (effective 2026-01-23).
“On January 23, 2026, in anticipation of the initial closing of the Offering (as defined below), Daré Bioscience, Inc. (“Daré” “we,” “us,” or “our”) filed a Certificate of Designation of Series A Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, which became effective upon filing.”
Dare Bioscience, Inc. terminated License Agreement with Bayer HealthCare LLC (effective 2026-02-24).
“On November 26, 2025, Daré Bioscience, Inc. (“we,” “us”, “our,” or the “Company”) received notice from Bayer HealthCare LLC (“Bayer”) that it was terminating the license agreement between the parties dated January 10, 2020 (the “License Agreement”).”
Dare Bioscience, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
“February 13, 2025, Nasdaq’s Listing Qualifications Department (the “Staff”) notified the Company that because the Company did not timely regain compliance with the Minimum MVLS Rule by February 10, 2025, the Company’s common stock is subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Panel”). The Company will timely request a hearing before the Panel, which request will stay the delisting of the Company’s common stock pending the Panel’s decision following the hearing and the expiration of any extension period that the Panel may”
Dare Bioscience, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
“February 13, 2025, Nasdaq’s Listing Qualifications Department (the “Staff”) notified the Company that because the Company did not timely regain compliance with the Minimum MVLS Rule by February 10, 2025, the Company’s co”
Dare Bioscience, Inc. reported financial results for the quarter ended March 31, 2024.
“Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2024, a copy of which is furnished as Exhibit 99.1 to this report.”
Dare Bioscience, Inc. entered into Synthetic Royalty Purchase Agreement with XOMA (US) LLC (effective 2024-04-29).
“On April 29, 2024, Daré Bioscience, Inc. (“Daré” or the “Company”) entered into a Traditional Royalty Purchase Agreement and a Synthetic Royalty Purchase Agreement (together, the “Agreements”) with XOMA (US) LLC (“XOMA”).”
Dare Bioscience, Inc. entered into Traditional Royalty Purchase Agreement with XOMA (US) LLC valued at $22.0 million (effective 2024-04-29).
“On April 29, 2024, Daré Bioscience, Inc. (“Daré” or the “Company”) entered into a Traditional Royalty Purchase Agreement and a Synthetic Royalty Purchase Agreement (together, the “Agreements”) with XOMA (US) LLC (“XOMA”). In accordance with the Agreements, on April 29, 2024, XOMA paid $22.0 million to Daré”
Dare Bioscience, Inc. reported financial results for the fiscal year ended December 31, 2023.
“On March 28, 2024, Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the fiscal year ended December 31, 2023”
Sabrina Martucci Johnson changed role as Chief Executive Officer and President at Dare Bioscience, Inc..
“Ms. Johnson, our Chief Executive Officer and President, will serve as our principal financial officer”
MarDee Haring-Layton was appointed as Chief Accounting Officer at Dare Bioscience, Inc..
“Ms. Haring-Layton, our current Vice President, Accounting & Finance, was appointed as our Chief Accounting Officer and will serve as our principal accounting officer.”
John Fair resigned as Chief Commercial Officer at Dare Bioscience, Inc..
“On January 24, 2024, John Fair, our Chief Commercial Officer, informed us that, in light of the full-scale commercial launch of XACIATO TM —bringing to fruition one of his primary responsibilities as Chief Commercial Officer—he will be resigning from all positions with us and his employment with us will end effective June 30, 2024.”
Lisa Walters-Hoffert retired as Chief Financial Officer at Dare Bioscience, Inc..
“On January 23, 2024, Lisa Walters-Hoffert informed Daré Bioscience, Inc. (“our,” “we”, “us,” “our,” or the “Company”) that she will retire from all positions with the Company, and her employment with the Company will end, effective January 26, 2024.”
Dare Bioscience, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“January 17, 2024, the Staff notified the Company that because the Company did not timely regain compliance with the Minimum Bid Price Requirement, the Company’s common stock is subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Panel”). The Company will timely request a hearing before the Panel, which request will stay the delisting of the Company’s common stock pending the decision of the Panel following the hearing and the expiration of any extension period that may be granted by the Panel. Pursuant to published Nasdaq guidance”
Dare Bioscience, Inc. entered into Royalty Interest Financing Agreement with United in Endeavour, LLC valued at up to $12 million (effective 2023-12-21).
“On December 21, 2023 (the “Effective Date”), Daré Bioscience, Inc. (the “Company”) entered into a Royalty Interest Financing Agreement (the “Agreement”) with United in Endeavour, LLC (“United”), pursuant to which the Company sold to United the right to receive certain royalty payments from the Company for a purchase price of up to $12 million.”
Dare Bioscience, Inc. reported financial results for the quarter ended September 30, 2023.
“On November 9, 2023, Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the quarter ended September 30, 2023”
Dare Bioscience, Inc. engaged Haskell & White LLP as its auditor.
“(the “Company”) approved the engagement of Haskell & White LLP (“H&W”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Dare Bioscience, Inc. entered into securities purchase agreement with two institutional investors valued at aggregate gross proceeds to Daré from the offering are expected to be $7.0 million (effective 2023-08-29).
“On August 29, 2023, Daré Bioscience, Inc. (the “Company” or “Daré”) entered into a securities purchase agreement with two institutional investors relating to the purchase and sale in a registered direct offering of an aggregate of (i) 10,000,000 shares of Daré’s common stock, and (ii) warrants to purchase an aggregate of 10,000,000 shares of Daré’s common stock.”
Dare Bioscience, Inc. reported financial results for the quarter ended June 30, 2023.
“Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the quarter ended June 30, 2023”
Dare Bioscience, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“July 19, 2023, Daré Bioscience, Inc. (“Daré”) received a letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying Daré that, for the last 30 consecutive business days, the closing bid price for Daré’s common stock was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq letter has no immediate effect on the listing of Daré’s common stock on the Nasdaq Capital Market. In accordance with Nasdaq listing”
Dare Bioscience, Inc. amended the Amendment with Organon International GmbH valued at $1.0 million (effective 2023-07-04).
“On July 4, 2023, Daré Bioscience, Inc. (“Daré”), and an affiliate of Organon & Co., Organon International GmbH (“Organon”), entered into an amendment (the “Amendment”) to the exclusive license agreement dated as of March 31, 2022 between the parties. Under the Amendment, Organon will pay $1.0 million to Daré to reimburse Daré for PDUFA fees and other manufacturing expenses and to support continued advancement of the development and commercialization of XACIATO, and the amount payable by Organon to Daré following the first commercial sale of a licensed product in the United States was revised to $1.8 million.”
Dare Bioscience, Inc. shareholders approved Advisory approval of compensation of named executive officers at the 2023-06-21 meeting.
“Our stockholders approved, on an advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement by the votes set forth below.”
Dare Bioscience, Inc. shareholders approved Ratification of appointment of Mayer Hoffman McCann P.C. as independent registered public accounting firm at the 2023-06-21 meeting.
“Our stockholders ratified the appointment of Mayer Hoffman McCann P.C.as our independent registered public accounting firm for the fiscal year ending December 31, 2023 by the votes set forth below.”
Dare Bioscience, Inc. shareholders approved Election of Class III directors at the 2023-06-21 meeting.
“Each of the director nominees was elected as a Class III director to hold office until our 2026 annual meeting of stockholders, and until a successor is duly elected and qualified, by the votes set forth below.”
Dare Bioscience, Inc. reported financial results for first fiscal quarter ended March 31, 2023.
“Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today reported financial results for the quarter ended March 31, 2023 and provided a company update.”
Dare Bioscience, Inc. entered into Sales Agreement with Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co. (effective 2023-03-31).
“On March 31, 2023, Daré Bioscience, Inc. (“we,” “us,” “our”), entered into a sales agreement (the “Sales Agreement”) with Stifel, Nicolaus & Company, Incorporated (“Stifel Nicolaus”) and Cantor Fitzgerald & Co. (“Cantor”) to sell shares of our common stock from time to time through an “at-the-market” equity offering program under which Stifel Nicolaus and Cantor will act as our sales agents (each individually a “Sales Agent” and together, the “Sales Agents”).”
Dare Bioscience, Inc. reported financial results for the quarter and fiscal-year ended December 31, 2022.
“On March 30, 2023, Daré Bioscience, Inc. issued a press release announcing its financial results for the quarter and fiscal-year ended December 31, 2022”
Dare Bioscience, Inc.: Amended and restated bylaws to update advance notice procedures, stockholder meeting provisions, officer duties, forum selection, and other conforming changes (effective 2023-01-24).
“On January 24, 2023, the board of directors of Daré Bioscience, Inc. (the “Company”) amended and restated the Company’s amended and restated by-laws effective as of such date.”
Dare Bioscience, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“December 16, 2022, Daré Bioscience, Inc. (“Daré”) received a letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying Daré that, for the last 30 consecutive business days, the closing bid price for Daré’s common stock was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq letter has no immediate effect on the listing of Daré’s common stock on the Nasdaq Capital Market. In accordance with Nasdaq list”
Dare Bioscience, Inc. reported financial results for the third quarter ended September 30, 2022.
“On November 10, 2022, Dare Bioscience, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.